Preview

Research and Practical Medicine Journal

Advanced search

MODERN POSSIBILITIES OF IMPORT SUBSTITUTION IN THE TREATMENT OF PAIN SYNDROME IN CANCER P ATIENTS

https://doi.org/10.17709/2409-2231-2014-1-1-8-15

Abstract

Objective. To evaluate the efficacy and safety of prosidol in cheek tablets in the treatment of chronic pain syndrome in cancer patients.

Material and methods. The study was conducted at 152 cancer patients with chronic pain syndrome caused by  malignant neoplasms. The objectification of pain intensity was conducted on a 5 — point verbal scale assessments (SVA), assessed the state of physical activity of patients on a 5‑point scale ECOG, objectified the mental status and a night’s sleep: 0‑no pain; 1 — slight pain; 2 — moderate pain; 3 — severe pain; 4 points unbearable pain. We registered the duration of analgesic effect of prosidol, calculated single and daily doses of analgesic in the dynamics on the stages of therapy and its side effects. The results of the study were assessed on stages: 1 — initial, before treatment, 2 — first day of therapy, 3 — completion of the selection of doses of analgesic (3–4 days), 4 — a week after the start of treatment, 5–2 weeks after the start of treatment, 6 — at the end of the 3rd week of treatment.

Results. Initial single dose of buccal prosidol (20 mg) caused effective analgesia after 10 to 45 (21,3+8,9) minutes after the first dose and lasted from 1 to 8 (6,0+1,8) hours: 21.8% of patients complete elimination of pain (more than 50% from baseline); in 63.6% of the pain was reduced by 30–50%; reduction of pain less than 30% — in 14.6% of patients. In General, a significant decrease in the intensity of pain with 2,47+0.37 to 0.5 to+0.30 VAS score (p<0.05). The failures of the drug were observed. All patients continued prosidol therapy after a 3‑week study period. The initial average daily dose of prosidol was 82.2 + 9,7 mg; 1 week of therapy — 112,3+16 mg, by the end of the 3rd week increased to 148,2+57 mg/day mg Tolerability was judged as good. Side effects: drowsiness and nausea most noted for 1–3 days of therapy was expressed moderately or weakly in 85% of patients (drowsiness of 62.3%, nausea is 27.3%, vomiting in 15%; dry mouth is 65.5%, dizziness) to 27.6%). Night sleep was stabilized at 85% (relative to 13% in the initial stage); the number of patients with symptoms of depression decreased in 1.8–2.2 times.

Conclusion. Buccal Procidol in a daily dose of from 60 to 200 mg provides effective analgesia in the majority of cancer patients with moderate to strong chronic pain at moderately pronounced side effects which are not dangerous, respond well to medical treatment. Procida in sublingual tablets possesses the basic properties required of modern medicine to opioid therapy for chronic cancer pain: it is effective, safe, better tolerated than other drugs,
convenient for the independent application of patients in outpatient and home. The lack of buccal prosidol is the short duration of effects (average 4 hours).

About the Authors

G. R. Abuzarova
Moscow O ncology Institute of the Hertsen FMRC MH RF (Moscow, Russian Federation) 3, 2 B otkinskiy proezd, 125284, Russian Federation, Moscow
Russian Federation

MD, head of center of oncological palliative care of Moscow Oncology Institute of the Hertsen FMRC MH RF 3, 2 Botkinskiy proezd, 125284, Russian Federation, Moscow Теl: + 7 (495) 945-88-55,



G. S. Alekseeva
Hertsen FMRC MH RF (Obninsk, Russian Federation) 4, st. Korolev, 249036, Russian Federation, Kaluga region, Obninsk
Russian Federation

MD, deputy director for clinical work, of P.A. Herzen Moscow Research Oncological Institute of the P.A. Herzen Federal Medical Research Center of Ministry of Health, Russian Federation



R. R. Sarmanaeva
Moscow O ncology Institute of the Hertsen FMRC MH RF (Moscow, Russian Federation) 3, 2 B otkinskiy proezd, 125284, Russian Federation, Moscow
Russian Federation

physician of center of oncological palliative care of P.A. Herzen Moscow Research Oncological Institute of the P.A. Herzen Federal Medical Research Center of Ministry of Health, Russian Federation



L. V. Dushakova
Hertsen FMRC MH RF (Obninsk, Russian Federation) 4, st. Korolev, 249036, Russian Federation, Kaluga region, Obninsk
Russian Federation

separation, document the diagnosis and treatment Moscow Oncology Institute of the Hertsen FMRC MH RF, Head of the Laboratory of the Department of Urology and Surgical Nephrology oncourology with the course of the Medical Faculty of the Medical Institute of People’s Friendship University



References

1. Obezbolivanie pri rake i palliativnoe lechenie: doklad komiteta jekspertov VOZ [Doklad]. - Zheneva : Vsemirnaja organizacija zdravoohranenija, 1992. - str. 76.

2. Obezbolivanie pri rake. - Zheneva : Vsemirnaja organizacija zdravoohranenija, 1992. - str. 76.

3. Osipova N.A., Novikov G.A., Prohorov B.M. Hronicheskij bolevoj sindrom v onkologii [Kniga]. - M : Medicina, 1998. - str. 187.

4. Osipova N.A., Novikov G.A., Prohorov B.M., i dr. Farmakoterapija hronicheskogo bolevogo sindroma u onkologicheskih bol’nyh // Posobie dlja vrachej. - M : MZ RF, 1997 g. - str. 27.

5. Zhurbanov B.A., Praliev K.D., Nurmuhabetova B.I., i dr. Bukkal’nye lekarstvennye formy analgetika prosidola [Zhurnal] // Him.-farmac. zhurn. - 1993 g. - T. 8. - str. 38-40.

6. Hilenko Zh.N., Moiseeva L.M. Prosidol - novoe lekarstvennoe credstvo. Farmakologija, klinika // Sb. nauch. trud. «Patofiziologija i farmakologija boli». - M : [b.n.], 1993 g. - str. 149.

7. Abuzarova G.R. Original’nyj otechestvennyj opioid prosidol v lechenii bolevyh sindromov [Zhurnal] // Anesteziologija i reanimatologija. - 2001 g. - T. 5. - str. 74-77.

8. Abuzarova G.R. Prosidol v lechenii hronicheskogo bolevogo sindroma u onkologicheskih bol’nyh // Avtoref. diss. kand. med. nauk. - M : [b.n.], 2001 g.

9. Novikov G.A. Osnovy palliativnoj pomoshhi onkologicheskim bol’nym s hronicheskoj bol’ju // Avtoref. diss. doktora med. nauk. - M : [b.n.], 1994 g.

10. Babajan Je.A., Gaevskij A.V., Bardin E.V. Pravovye aspekty oborota narkoticheskih, psihotropnyh, sil’nodejstvujushhih, jadovityh veshhestv i prekursorov. Normativnye dokumenty. Metodicheskie materialy. Otvety na voprosy [Kniga]. - M : Mezhdunarodnyj centr finansovo-jekonomicheskogo razvitija,

11. - str. 440.

12. Osipova G.R., Abuzarova G.R., Petrova V.V. Principy klinicheskogo primenenija narkoticheskih i nenarkoticheskih anal’geticheskih sredstv pri ostroj i hronicheskoj boli // Metodicheskie ukazanija MZ i SR RF. - M : [b.n.], 2005 g. - str. 80.

13. Brjuzgin V.V. Hronicheskij bolevoj sindrom u onkologicheskih bol’nyh [Kniga]. - M : Sb.nauch.trudov «Patofiziologija i farmakologija boli», 1993. - str. 61.

14. Brjuzgin V.V., Strelkova R.M. Novyj otechestvennyj analgetik prosidol i ego mesto v lechenii hronicheskoj boli u onkologicheskih bol’nyh [Razdel knigi] // Sb.nauchn.trudov «Novoe v onkologii». - Voronezh : [b.n.], 1997. - T. 2. - str. 212- 215.

15. Brjuzgin V.V. Novye vozmozhnosti i perspektivy lechenija hronicheskogo bolevogo sindroma u onkologicheskih bol’nyh [Zhurnal] // Farmateka. - 1998 g. - T. 2. - str. 34-35.

16. Isakova M.E., Pavlova Z.V. Lechenie bolevogo sindroma u onkologicheskih bo’nyh [Kniga]. - M : Medicina, 1980. - str. 128.

17. Isakova M.E., Pavlova Z.V., Laktionov K.P. Prosidol – novyj perspektivnyj analgetik v onkologii [Zhurnal] // Vpervye v medicine. - 1995 g. - T. 1. - str. 34.

18. Isakova M.E., Pavlova Z.V., Cirihov S.M., Glazova L.V. Novyj analgetik central’nogo dejstvija prosidol v onkologii [Konferencija] // Tez. dokl. 1-go Rossijskogo nacinal’nogo kongressa «Chelovek i lekarstvo». - 1992. - str. 145.

19. Kurilenko V.M., Mihajlova N.N., Slepushkin V.D., Ulanova E.V. Izuchenie novoj lekarstvennoj formy prosidola na jeksperimental’noj modeli travmaticheskogo shoka [Konferencija] // Tez . dokl. Vserossijskoj nauchno-prakticheskoj konferencii «Aktual’nye voprosy mediciny katastrof». - Novosibirsk : [b.n.], 1994. - str. 56-57.

20. Luk’janova M.S., Baeva T.N., Ivanova R.A. Farmakokinetika i raspredelenie prosidola v tkanjah organov jeksperemental’nyh zhivotnyh [Konferencija] // Tez. dokl. 2-j konferencii Rossijskoj associi po izucheniju boli, 12-15 sent. 1995 g. - M : [b.n.], 1995. - str. 203-204.

21. Moiseeva L.M., Mal’ceva L.F., Romanova T.V. i dr. Izuchenie specificheskoj aktivnosti i toksichnosti prosidola na nepolovozrelyh zhivotnyh [Konferencija] // Tez. dokl. 2-j konferencii Rossijskoj associi po izucheniju boli, 12-15 sent. 1995 g. - M : [b.n.], 1995. - str. 308-309.

22. Moiseeva L.M.,Hilenko Zh.N.,Kurilenko V.M.i dr. Farmakologicheskoe izuchenie novoj lekarstvennoj formy prosidola dlja bukkal’nogo primenenija [Razdel knigi] // Sb.nauch.trud. «Patofiziologija i farmakologija boli». - M : [b.n.], 1993. – str.142.

23. Brjanskaja A.P. Lechenie hronicheskogo bolevogo sindroma prosilom u bol’nyh u bol’nyh s ishemicheskimi boljami v nizhnih konechnostjah // Avtoref. diss. kand. med. nauk. - SPb : [b.n.], 1995 g.

24. Brjanskaja F.P., Strashnov V.I.,Dubitkajtis A.Ju. Ocenka boleutoljajushhego dejstvija prosidola pri kupirovanii hronicheskogo bolevogo sindroma v dooperacionnom periode u bol’nyh s ishemicheskimi boljami v nizhnih konechnostjah [Konferencija] // Tez. dokl. 2-j konferencii Rossijskoj associi po izucheniju boli, 12-15 sent. 1995 g. - M : [b.n.], 1995. - str. 143- 147.

25. Nikoda V.V. Primenenie otechestvennogo anal’getika prosidola v posleoperacionnom periode [Zhurnal] // Anesteziologija i reanimatologija. - 1997 g. - T. 5. - str. 102-103.

26. Osipova N.A., Novikov G.A., Vetsheva M.A., Prohorov B.M., i dr. Pervyj opyt primenenija novogo otechestvennogo narkoticheskogo analgetika prosidola v onkologii [Zhurnal] // Anesteziologija i reanimatologija. - 1994 g. - T. 4. - str. 53-57.

27. Poljakov V.S. Prosidol – novyj vysokojeffektivnyj analgetik [Zhurnal] // Farmateka. - 1994 g. - T. 4. - str. 9-11.


Review

For citations:


Abuzarova G.R., Alekseeva G.S., Sarmanaeva R.R., Dushakova L.V. MODERN POSSIBILITIES OF IMPORT SUBSTITUTION IN THE TREATMENT OF PAIN SYNDROME IN CANCER P ATIENTS. Research and Practical Medicine Journal. 2014;1(1):8-15. (In Russ.) https://doi.org/10.17709/2409-2231-2014-1-1-8-15

Views: 1661


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2410-1893 (Online)